Medical Supply Chain Resiliency Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,649 other S bills in the 118th — cohort avg 33d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (15)
Read twice and referred to the Committee on Finance.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2025 · first_quarter · Trade (domestic/foreign)
CFIUS and Foreign Investment Drug Importation Drug Pricing ---Reference Pricing in Drug Reimbursement Foreign Agricultural Biotechnology Laws and Regulations ---China Biotechnology Regulations ---EU Ag-Biotech Policies and Regulations ---International Consistency of Regulation for Gene Edited Products ---Korea Biotechnology Regulations ---Mexico Decree Banning Genetically Modified Corn Foreign Drug Data Protection Laws ---BIOSECURE Act ---Protecting Americans Data from Foreign Adversaries Act ---A bill to prohibit contracting with certain biotechnology providers, and for other purposes. ---Bio COMPETES (Draft) ---Executive Order on Preventing Access to Americans Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern ---House GOP RFI on Supply Chain Genetically Engineered (GE) Animals ---International Consistency of Regulation for Gene Edited Products Genetically Engineered (GE) Plants ---International Consistency of Regulation for Gene Edited Products Global Supply Chain Resiliency ---B5 Coalition on Supply Chain Resiliency ---Issues Relating to Non-Human Primate Shortages Intellectual Property International Enforcement ---China S.2115/H.R.4307 - Medical Supply Chain Resiliency Act Synthetic Biotech Pharmaceutical and Ag Biotech Tariffs US-China Trade Agreement ---Ag-Biotech Provisions ---IP Provisions World Health Organization (WHO) ---WHO Pandemic Preparedness Accord World Intellectual Property Office (WIPO) ---Treaty on Intellectual Property, Genetic Resources, and Associated Traditional Knowledge World Trade Organization (WTO) ---TRIPS Waiver
Client expense: $890,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · first_quarter · Health Issues
H.R. 661, MIRACLE Medical Technology Act of 2025 H.R. 1650/S. 763, Telehealth Expansion Act of 2025 Potential legislation similar to H.R. 1843/S. 1001, Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 2868, Association Health Plans Act Potential legislation similar to H.R. 3800, Chronic Disease Flexible Coverage Act Potential legislation similar to H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act Potential legislation similar to H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 Potential legislation similar to H.R. 6860, Restore Protections for Dialysis Patients Act Potential legislation similar to H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 Potential legislation similar to S. 142, Preserve Access to Affordable Generics and Biosimilars Act Potential legislation similar to S. 150, Affordable Prescriptions for Patients Act of 2023 Potential legislation similar to S. 1067, Ensuring Timely Access to Generics Act of 2023 Potential legislation similar to S. 1114, Expanding Access to Low-Cost Generics Act of 2023 Potential legislation similar to S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Potential legislation similar to S. 2780, The Medication Affordability and Patent Integrity Act Final Rule, Mental Health Parity and Addiction Equity Act (89 Fed. Reg. 77,586-77,751, September 23, 2024) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; support for continued and reformed U.S. foreign assistance, including in global health; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
2025 · first_quarter · Trade (domestic/foreign)
Tariff policy U.S.-EU trade U.S.-UK trade USMCA Enforcement Universal Postal Union Access and Reform H.R. 4307/ S.2115 - Medical Supply Chain Resiliency Act: Promotes a trusted trader network for the movement of essential medical goods across borders. The legislation will improve U.S. access, and ensure that critical goods can be delivered safely, swiftly, and efficiently to patients at home and around the world.
Client expense: $2,330,000 · Firm income: Not reported
2024 · fourth_quarter · Trade (domestic/foreign)
International Supply Chain HR 4307/S 2115 - Medical Supply Chain Resiliency Act
Client expense: $1,600,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
2024 · fourth_quarter · Trade (domestic/foreign)
International Supply Chain HR 4307/S 2115 - Medical Supply Chain Resiliency Act
Client expense: $2,390,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
Client expense: $19,340,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR)
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, Small Business Administration (SBA), State, Dept of (DOS), U.S. Trade Representative (USTR)
2024 · fourth_quarter · Trade (domestic/foreign)
International Supply Chain HR 4307/S 2115 - Medical Supply Chain Resiliency Act
Client expense: $2,830,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
2024 · fourth_quarter · Trade (domestic/foreign)
H.R. 3334: STOP CCP Act H.R. 4307: Medical Supply Chain Resiliency Act H.R. 8333: BIOSECURE Act S. 1956: Invent Here, Make Here Act of 2024 S. 2115: Medical Supply Chain Resiliency Act Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues
Client expense: $920,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2024 · fourth_quarter · Trade (domestic/foreign)
Issues related to promoting a trade agenda on health-related issues, including H.R.4307/S.2115 - Medical Supply Chain Resiliency Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Trade (domestic/foreign)
H.R. 3334: STOP CCP Act H.R. 4307: Medical Supply Chain Resiliency Act H.R. 8333: BIOSECURE Act S. 1956: Invent Here, Make Here Act of 2024 S. 2115: Medical Supply Chain Resiliency Act Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues
Client expense: $7,560,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Trade (domestic/foreign)
Tariff policy U.S.-EU trade U.S.-UK trade IPEF USMCA Enforcement Universal Postal Union Access and Reform H.R. 4307/ S.2115 - Medical Supply Chain Resiliency Act: Promotes a trusted trader network for the movement of essential medical goods across borders. The legislation will improve U.S. access, and ensure that critical goods can be delivered safely, swiftly, and efficiently to patients at home and around the world. S 986 - STOP Act 2.0 - makes it illegal for foreign shippers to mis-represent the origin of international postal shipments and increases customs and security compliance visibility
Client expense: $1,130,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, Small Business Administration (SBA), State, Dept of (DOS), U.S. Trade Representative (USTR)
2024 · fourth_quarter · Trade (domestic/foreign)
International Supply Chain HR 4307/S 2115 - Medical Supply Chain Resiliency Act
Client expense: $2,760,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
2024 · fourth_quarter · Health Issues
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act H.R. 3800, Chronic Disease Flexible Coverage Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6363, Further Continuing Appropriations and Other Extensions Act of 2024, and issues pertaining to H.R. 1843/S. 1001, The Telehealth Expansion Act of 2023 H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 S. 2780, The Medication Affordability and Patent Integrity Act Proposed Rule, Internal Revenue Service, the Employee Benefits Security Administration, and the Health and Human Services Department; Requirements Related to the Mental Health Parity and Addiction Equity Act (88 Fed. Reg. 51,552-51,669, August 3, 2023) Proposed Rule, Employee Benefits Security Administration, Department of Labor; Definition of Employer-Association Health Plans (88 Fed. Reg. 87,968-87,981, December 20, 2023) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); over-the-counter preventive services; ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; combatting anti-microbial resistance; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Client expense: $22,410,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR)
2024 · fourth_quarter · Trade (domestic/foreign)
H.R. 813, Global Investment in American Jobs Act H.R. 3739/S. 2343, For Accurate Import Relief To Aid Retailers and Importers of Foreign Freights (FAIR TARIFF) Act of 2023 H.R. 3882/S. 1856, Leveling the Playing Field Act 2.0 H.R. 4184, Import Security and Fairness H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 5614/S. 552, Haiti Economic Lift Program Extension Act of 2023 H.R. 6349, Preventing Adversaries from Developing Critical Capabilities Act H.R. 6555, CNL Update Act of 2023 H.R. 6990, Digital Trade for Development Act H.R. 7979, End China's De Minimis Abuse Act H.R. 8152, Remote Access Security Act H.R. 9026/S. 2321, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2025 H.R. 9563, Protecting Americans from Russian Litigation Act S. 1421, Country of Origin Labeling (COOL) Online Act S. 4110, AGOA Renewal and Improvement Act of 2024 S. 2321, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2024 Draft legislation titled Comprehensive Outbound Investment National Security (COINS) Act of 2024 Draft legislation titled Detection and Exclusion of Negligent, Illicit, and Extralegal Deliveries (DENIED) Act Draft legislation titled Haitian Hemispheric Opportunity through Partnership Encouragement Draft legislation titled HELP Extension Act Notice Proposed Rule on Provisions Pertaining to U.S. Investments in Certain National Security Technologies and Products in Countries of Concern (89 Fed. Reg 55,846-55,881, July 5, 2024) Various issues relating to U.S.-Korea digital trade and services; Generalized System of Preferences (GSP) reauthorization; ratification of the Assignment of Receivables in International Trade Convention; reform of the World Trade Organization (WTO); reforms to export controls; digital trade; investor protections in trade agreements; implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of the Uyghur Forced Labor Prevention Act (UFLPA) (P.L. 117-78); implementation of the Creating Helpful Incentives to Produce Semiconductors (CHIPS) and Science Act, (P.L. 117-167); reform of Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); reform of Section 301 of the Trade Act of 1974 (P.L. 93-618), including establishment of exclusion process; implementation of the African Growth and Opportunity Act (P.L. 106-200); International Emergency Economic Powers Act (IEEPA), Title II of (P. L. 95-223); implementation of the INFORM Consumers Act, Div. BB, Title III of (P. L. 117-328); implementation of the Inflation Reduction Act, (P.L. 117-169); reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); pharmaceutical price controls; implementation of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; efforts related to the reauthorization of the African Growth and Opportunity Act (AGOA) (P.L. 106-200); efforts related to issues related to regulations issued by the Bank of Central African States (BEAC); China's intellectual property regime, industrial policies, and cyber security; implementation of the U.S.- China economic and trade agreement; IP issues relating to trade secret theft; IP issues relating to internet counterfeiting and digital piracy; IP issues relating to artificial intelligence; implementation of U.S. sanctions on Russia, including those related to Russias threats to and invasion of Ukraine; efforts related to sustaining momentum on providing aid to Ukraine; U.S.-EU negotiations on a legal data transfer mechanism; U.S.-EU energy and sustainability cooperation; United States-India Trade Policy Forum; EU and international tax policy including digital tax proposals; U.S.-EU Trade & Technology Council; EU-U.S. Joint Technology Competition Policy Dialogue; EU Digital Markets Act; EU Digital Services Act; EU Data Act; EU AI Act; EU Carbon Border Adjustment Mechanism; EU digital sovereignty and regulatory agenda; European Cybersecurity Certification Scheme for Cloud Services (EUCS); Global Internet Governance; Global Cross Border Privacy Rules Forum; policies and regulations restricting outbound data flows and data transfers; digital-related policies in the G20, G7, OECD, United Nations, and other international fora; Indias Information Communications Technology (ICT) Tariffs; Federal Trade Commission statutory authority under Section 19 of the Federal Trade Commission Act of 1914; efforts to modernize the Committee on Foreign Investment in the United States (CFIUS); efforts related to the National Defense Authorization Act for Fiscal Year 2025; efforts to preserve investment protections such as investor-state dispute settlement; efforts related to outlining critical mineral opportunities with key allies; efforts related to the 2024 Farm Bill; efforts related to opposing international imposition of digital services taxes; related efforts supporting strong digital trade rules; efforts to modify permanent normal trade relations treatment with China; U.S. economic and commercial relations with key trading partners across the globe; efforts to draft and implement an outbound investment screening mechanism; efforts related to establishing a domestic carbon border tax mechanism, foreign pollution fees; efforts related to modernizing customs processes and updating tariff application procedures including revisions to the de minimis statute; efforts related to boosting trade relations with the Latin American region; efforts related to electric vehicle tax credit incentives in the Inflation Reduction Act (P.L. 117-169); efforts related to the development and implementation of the Indo-Pacific Economic Framework (IPEF); efforts related to the development and negotiation of the U.S.-Taiwan Initiative on 21st Century Trade: efforts related to the development and negotiation of the Americas Partnership for Economic Prosperity (APEP); efforts related to the development and negotiation of the U.S.-UK Dialogue on the Future of Atlantic Trade; efforts related to the development and negotiation of the U.S.-Kenya Strategic Trade and Investment Partnership; efforts to significantly revise U.S. antidumping and countervailing duty law; efforts to provide financial support, trade facilitation, and infrastructure support to the African Continental Free Trade Area (AfCFTA); implementation and enforcement of U.S. free-trade agreements in force with Canada and Mexico (the United States-Mexico-Canada Agreement), the Dominican Republic-Central America Free Trade Agreement (CAFTA-DR FTA), Colombia and South Korea; implementation and enforcement of the agreements and ongoing negotiations of the World Trade Organization (WTO); efforts related to the Export-Import Bank (Ex-Im Bank); trade policy consideration addressing cross-border data flows and issues of forced localization, and forced disclosure of source code; international trade and regulatory practices impacting digital goods and services; international competition policy and related regulations; international artificial intelligence policy; international 5G policy and telecommunications infrastructure; international cybersecurity policy; international policies on standards development; international policies on data privacy; international digital health policies; international policies related to content moderation and intermediary liability; advancing international regulatory cooperation; competition policy and related regulations; consumer protection policy and related regulations; efforts related to the U.S.-Bangladesh Trade and Investment Cooperation Forum Agreement (TICFA); efforts related to the resumption of the U.S.-Bangladesh High Level Economic Consultation; efforts related to the U.S.-India Innovation Handshake and the India-U.S. Defense Acceleration Ecosystem (INDUS-X); steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and the United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; trade negotiations and trade priorities between the U.S. and China; U.S.-Brazil trade; Pacific Digital Trade Agreements; east coast port trade negotiations, closures, and strikes; U.S. Chile Tax Treaty, Convention for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital; U.S. Trade Representative section 301 investigation of Frances digital services tax; efforts to pass the Miscellaneous Tariff bill; Trade Promotion Authority (TPA) reauthorization and reform; Russian sovereign debt; Commercial Service Office in Bangladesh; Indo-Pacific Economic Framework and associated issues, digital trade de minimis level for duty free clearance of low value goods, competition provisions; patent examination practices and patent quality measures; tech transfer frameworks under the Bayh-Dole Act (P.L. 96-517); recommendations for Export Controls Cooperation at the U.S.-EU Trade and Technology Council; adoption of digital clothing labels; international competition policy, specifically FTC and DOJ involvement in the European Unions implementation of the EU Digital Markets Act; compliance with sanctions on the Russian Federation and potential legal penalties in Russian courts for U.S. companies; proposal for General License Authorizing Private Commercial Arbitration Proceedings Involving Blocked Persons; The United States Trade Representatives decision to withdraw support for digital trade in the context of World Trade Organizations e-commerce negotiations; support for robust global framework for facilitation of digital trade through the ongoing joint statement initiative on e-commerce (JSI); Indonesia Ministry of Trade Import Licensing Regulations; Committee on Foreign Investment in the United States (CFIUS) concerns, specifically regarding the U.S. Governments foreign investment review of Nippon Steels proposed acquisition of U.S. Steel; supply chain and defense industrial base issues; printed circuit boards; Foreign Assistance Act for Fiscal Year 2024; development of the National Defense Authorization Act for Fiscal Year 2025; implementation of the National Defense Authorization Act for Fiscal Year 2024; customs reauthorization
Client expense: $22,410,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Executive Office of the President (EOP), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
2024 · fourth_quarter · Health Issues
340B legislation. Issues related to vaccine injury compensation funds. S.2115/H.R.4307 - Medical Supply Chain Resiliency Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Trade (domestic/foreign)
International Supply Chain HR 4307/S 2115 - Medical Supply Chain Resiliency Act
Client expense: $2,710,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
2024 · fourth_quarter · Health Issues
Incentivizing domestic manufacturing of critical medical supplies Issues related to health care costs and transparency Electronic prior authorization and administrative simplification Health care supply chain resiliency 340B Drug discount program Reauthorization of Pandemic and All Hazards Preparedness Act Hospital finance issues Healthcare workforce issues (graduate medical education, health professional training, recruitment and retention, minimum staffing requirements) Medicare payment policies Alternative payment models and related policies Medicare home infusion policy Reauthorization of Substance-Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act Expanding access to interoperable health tech in long term and post-acute care settings Maternal and infant health Health care workplace violence and worker safety S. 148 Stop STALLING Act S. 150 Affordable Prescriptions for Patients Act Medicaid Disproportionate Hospital Share cuts S. 2115, H.R. 4307 Medical Supply Chain Resiliency Act H.R. 4104, S. 1976 Preseving Patients Access to Home Infusion Act H.R. 2584, S. 2768 SAVE Act H.R. 3577 Medical and Health Stockpile Accountability Act H.R. 2665 Supporting Safety Net Hospitals Act H.R. 2389, S. 1302 Resident Physician Shortage Reduction Act H.R. 3346 IMPACT to Save Moms Act H.R. 5378 Lower Costs, More Transparency Act S. 2840 Bipartisan Primary Care and Health Workforce Act H.R. 5013, S. 3503 Value in Health Care Act H.R. 4942, S. 665 Conrad State 30 and Physician Access Reauthorization Act Artificial intelligence in healthcare H.R.766, S. 114 Preventive Health Savings Act H.R. 6205, S. 3211 Healthcare Workforce Resilience Act H.R. 7050 Substance Use Disorder Workforce Act H.R. 8702, S. 4532 Improving Seniors' Timely Access to Care Act H.R. 7855 Rural Residency Planning and Development Act
Client expense: $180,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Health Issues
H.R. 5013, the Value in Health Care Act, all provisions. H.R. 2584, the SAVE Act of 2023, all provisions. H.R. 4307 and S. 2115, the Medical Supply Chain Resiliency Act, all provisions. Requested signatures on a letter opposing a company's unilateral decision to change their form of participation in the 340B Drug Discount Program.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · fourth_quarter · Health Issues
H.R. 766, Preventive Health Savings Act S. 114, Preventive Health Savings Act H.R. 10545, American Relief Act, 2025 H.R. 2888, ONSHORE Manufacturing Act S. 44, ONSHORE Manufacturing Act H.R. 4307, Medical Supply Chain Resiliency Act S. 2115, Medical Supply Chain Resiliency Act H.R. 6033, Supporting Patient Education and Knowledge Act H.R. 7165, Credit for Caring Act S. 3702, Credit for Caring Act S. 2333, Pandemic and All-Hazards Preparedness and Response Act Office of the National Coordinator for Health Information Technology--Health Data, Technology, and Interoperability: Patient Engagement, Information Sharing, and Public Health Interoperability (HTI-2) Proposed Rule (RIN 0955-AA06)
Client expense: $100,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2024 · third_quarter · Trade (domestic/foreign)
International Supply Chain HR4307/S2115 - Medical Supply Chain Resiliency Act
Client expense: $1,070,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
2024 · third_quarter · Trade (domestic/foreign)
H.R. 4307: Medical Supply Chain Resiliency Act H.R. 7085: BIOSECURE Act S. 1956: Invent Here, Make Here Act of 2023 S. 2115: Medical Supply Chain Resiliency Act S. 3558: BIOSECURE Act Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues
Client expense: $1,540,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
H.R. 4307: Medical Supply Chain Resiliency Act S. 1834/H.R. 3858: No Free TRIPS Act S. 845: Short on Competition Act S. 2115: Medical Supply Chain Resiliency Act Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues
Client expense: $740,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office
2024 · third_quarter · Health Issues
Incentivizing domestic manufacturing of critical medical supplies Issues related to health care costs and transparency Electronic prior authorization and administrative simplification Health care supply chain resiliency 340B Drug discount program Reauthorization of Pandemic and All Hazards Preparedness Act Hospital finance issues Healthcare workforce issues (graduate medical education, health professional training, recruitment and retention, minimum staffing requirements) Medicare payment policies Alternative payment models and related policies Medicare home infusion policy Reauthorization of Substance-Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act Expanding access to interoperable health tech in long term and post-acute care settings Maternal and infant health Health care workplace violence and worker safety S. 148 Stop STALLING Act S. 150 Affordable Prescriptions for Patients Act Medicaid Disproportionate Hospital Share cuts S. 2115, H.R. 4307 Medical Supply Chain Resiliency Act H.R. 4104, S. 1976 Preseving Patients Access to Home Infusion Act H.R. 2584, S. 2768 SAVE Act H.R. 3577 Medical and Health Stockpile Accountability Act H.R. 2665 Supporting Safety Net Hospitals Act H.R. 2389, S. 1302 Resident Physician Shortage Reduction Act H.R. 3346 IMPACT to Save Moms Act H.R. 5378 Lower Costs, More Transparency Act S. 2840 Bipartisan Primary Care and Health Workforce Act H.R. 5013, S. 3503 Value in Health Care Act H.R. 4942, S. 665 Conrad State 30 and Physician Access Reauthorization Act Artificial intelligence in healthcare H.R.766, S. 114 Preventive Health Savings Act H.R. 6205, S. 3211 Healthcare Workforce Resilience Act H.R. 7050 Substance Use Disorder Workforce Act H.R. 8702, S. 4532 Improving Seniors' Timely Access to Care Act H.R. 7855 Rural Residency Planning and Development Act
Client expense: $173,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Trade (domestic/foreign)
Tariff policy U.S.-EU trade U.S.-UK trade IPEF USMCA Enforcement H.R. 4307/ S.2115 - Medical Supply Chain Resiliency Act: Promotes a trusted trader network for the movement of essential medical goods across borders. The legislation will improve U.S. access, and ensure that critical goods can be delivered safely, swiftly, and efficiently to patients at home and around the world. S 986 - STOP Act 2.0 - makes it illegal for foreign shippers to mis-represent the origin of international postal shipments and increases customs and security compliance visibility S 5284 - Stop Smuggling Illicit Synthetic Drugs on U.S. Transportation Networks Act of 2024 Fighting Illicit Goods, Helping Trustworthy Importers, and Netting Gains (FIGHTING) for America Act
Client expense: $1,250,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, Small Business Administration (SBA), State, Dept of (DOS), U.S. Trade Representative (USTR)
2024 · third_quarter · Health Issues
Implementation of the drug pricing provisions in the Inflation Reduction Act Access to Prescription Digital Therapeutics Act (H.R. 1458)S. 2115/H.R. 4307 the Medical Supply Chain Resiliency Act H.R. 8816, the American Medical Innovation and Investment Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Trade (domestic/foreign)
H.R. 813, Global Investment in American Jobs Act H.R. 3739/S. 2343, For Accurate Import Relief To Aid Retailers and Importers of Foreign Freights (FAIR TARIFF) Act of 2023 H.R. 3882/S. 1856, Leveling the Playing Field Act 2.0 HR 4184, Import Security and Fairness H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 5614/S. 552, Haiti Economic Lift Program Extension Act of 2023 H.R. 6349, Preventing Adversaries from Developing Critical Capabilities Act H.R. 6555, CNL Update Act of 2023 H.R. 6990, Digital Trade for Development Act H.R. 7571/S. 3878, The Americas Act H.R.7962, United States Trade Leadership in the Indo-Pacific Act H.R. 7979, End China's De Minimis Abuse Act H.R.8299, Maximizing Israel-U.S. Research Advancement and Collaborative Leadership in Emerging Medical Technology Act of 2024 H.R.8924 - PAID Act of 2024 H.R. 9026/S. 2321, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2025 H.R. 9563, Protecting Americans from Russian Litigation Act S. 913, Innovation and Development in Ecuador (IDEA) Act of 2023 S.1325, Western Hemisphere Partnership Act of 2023 S.1421, Country of Origin Labeling (COOL) Online Act S.1926, United States-Uruguay Economic Partnership Act S.4110, AGOA Renewal and Improvement Act of 2024 H. Res. 1056, Recognizing the importance of trilateral cooperation among the United States, Japan, and South Korea Draft legislation titled the U.S. - Republic of Korea Digital Trade Enforcement Act Notice Proposed Rule on Provisions Pertaining to U.S. Investments in Certain National Security Technologies and Products in Countries of Concern (89 Fed. Reg 55846, 55,846-55,881, July 5, 2024) Various issues relating to U.S.-Korea digital trade and services; Generalized System of Preferences (GSP) reauthorization; ratification of the Assignment of Receivables in International Trade Convention; reform of the World Trade Organization (WTO); reforms to export controls; digital trade; investor protections in trade agreements; implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of the Uyghur Forced Labor Prevention Act (UFLPA) (P.L. 117-78); implementation of the Creating Helpful Incentives to Produce Semiconductors (CHIPS) and Science Act, (P.L. 117-167); reform of Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); reform of Section 301 of the Trade Act of 1974 (P.L. 93-618), including establishment of exclusion process; implementation of the African Growth and Opportunity Act (P.L. 106-200); International Emergency Economic Powers Act (IEEPA), Title II of (P. L. 95-223); implementation of the INFORM Consumers Act, Div. BB, Title III of (P. L. 117-328); implementation of the Inflation Reduction Act, (P.L. 117-169); implementation of the Build America, Buy America Act (BABA) statute contained in the Infrastructure Investment and Jobs Act (P.L. 117-58); Foreign Assistance Act for Fiscal Year 2024; development of the National Defense Authorization Act for Fiscal Year 2025; implementation of the National Defense Authorization Act for Fiscal Year 2024; reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); pharmaceutical price controls; domain name system abuse and related IP issues; implementation of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; efforts related to the reauthorization of the African Growth and Opportunity Act (AGOA) (P.L. 106-200); efforts related to issues related to regulations issued by the Bank of Central African States (BEAC); China's intellectual property regime, industrial policies, and cyber security; implementation of the U.S.- China economic and trade agreement; IP issues relating to trade secret theft; IP issues relating to internet counterfeiting and piracy; IP issues relating to artificial intelligence; implementation of U.S. sanctions on Russia including those related to Russias threats to and invasion of Ukraine; efforts related to sustaining momentum on providing aid to Ukraine; U.S.-EU negotiations on a legal data transfer mechanism; U.S.-EU energy and sustainability cooperation; United States-India Trade Policy Forum; EU and international tax policy including digital tax proposals; U.S.-EU Trade & Technology Council; EU-U.S. Joint Technology Competition Policy Dialogue; EU Digital Markets Act; EU Digital Services Act; EU Data Act; EU AI Act; EU Carbon Border Adjustment Mechanism; EU digital sovereignty and regulatory agenda; European Cybersecurity Certification Scheme for Cloud Services (EUCS); Global Internet Governance; Global Cross Border Privacy Rules Forum; policies and regulations restricting outbound data flows and data transfers; digital-related policies in the G20, G7, OECD, and other international fora; Indias Information Communications Technology (ICT) Tariffs; Federal Trade Commission statutory authority under Section 19 of the Federal Trade Commission Act of 1914; efforts to modernize the Committee on Foreign Investment in the United States (CFIUS); efforts related to the National Defense Authorization Act for Fiscal Year 2025; efforts to preserve investment protections such as investor-state dispute settlement; efforts related to outlining critical mineral opportunities with key allies; efforts related to the 2024 Farm Bill; efforts related to opposing international imposition of digital services taxes; related efforts supporting strong digital trade rules; efforts related to the negotiation of the U.S. - EU Arrangements on Global Steel and Aluminum Excess Capacity and Carbon Intensity; efforts to modify permanent normal trade relations treatment with China; U.S. economic and commercial relations with key trading partners across the globe; efforts to draft and implement an outbound investment screening mechanism; efforts related to establishing a domestic carbon border tax mechanism, foreign pollution fees; efforts related to modernizing customs processes and updating tariff application procedures including revisions to the de minimis statute; efforts to revise country of origin labeling requirements for animal and online products; efforts related to boosting trade relations with the Latin American region; efforts related to electric vehicle tax credit incentives in the Inflation Reduction Act (P.L. 117-169); efforts related to the development and implementation of the Indo-Pacific Economic Framework (IPEF); efforts related to the development and negotiation of the U.S.-Taiwan Initiative on 21st Century Trade; efforts related to the development and negotiation of the Americas Partnership for Economic Prosperity (APEP); efforts related to the development and negotiation of the U.S.-UK Dialogue on the Future of Atlantic Trade; efforts related to the development and negotiation of the U.S.-Kenya Strategic Trade and Investment Partnership; efforts to significantly revise U.S. antidumping and countervailing duty law; efforts to provide financial support, trade facilitation, and infrastructure support to the African Continental Free Trade Area (AfCFTA); implementation and enforcement of U.S. free-trade agreements in force with Canada and Mexico (the United States-Mexico-Canada Agreement), the Dominican Republic-Central America Free Trade Agreement (CAFTA-DR FTA), Colombia and South Korea; Implementation and enforcement of the agreements and ongoing negotiations of the World Trade Organization (WTO); efforts related to the Export-Import Bank (Ex-Im Bank); trade policy consideration addressing cross-border data flows and issues of forced localization, and forced disclosure of source code; international trade and regulatory practices impacting digital goods and services; international competition policy and related regulations; international artificial intelligence policy; international 5G policy and telecommunications infrastructure; international cybersecurity policy; international policies on standards development; international policies on data privacy; international digital health policies; international policies related to content moderation and intermediary liability; advancing international regulatory cooperation; competition policy and related regulations; consumer protection policy and related regulations; efforts related to the U.S.-Bangladesh Trade and Investment Cooperation Forum Agreement (TICFA); efforts related to the resumption of the U.S.-Bangladesh High Level Economic Consultation; efforts related to the U.S.-India Innovation Handshake and the India-U.S. Defense Acceleration Ecosystem (INDUS-X); steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and the United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; trade negotiations and trade priorities between the U.S. and China; U.S.-Brazil trade; Pacific Digital Trade Agreements; East Coast port trade negotiations, closures, and strikes; U.S. Chile Tax Treaty, Convention for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital; U.S. Trade Representative section 301 investigation of Frances digital services tax; efforts to pass the Miscellaneous Tariff bill; Trade Promotion Authority (TPA) reauthorization and reform; Russian sovereign debt; Commercial Service Office in Bangladesh; Indo-Pacific Economic Framework and associated issues, digital trade de minimus level for duty free clearance of low value goods, competition provisions; patent examination practices and patent quality measures; tech transfer frameworks under the Bayh-Dole Act (P.L. 96-517); recommendations for Export Controls Cooperation at the U.S.-EU Trade and Technology Council; adoption of digital clothing labels; international competition policy, specifically FTC and DOJ involvement in the European Unions compliance with sanctions on the Russian Federation and potential legal penalties in Russian courts for U.S. companies; proposal for General License Authorizing Private Commercial Arbitration Proceedings Involving Blocked Persons; The United States Trade Representatives decision to withdraw support for digital trade in the context of World Trade Organizations e-commerce negotiations; support for robust global framework for facilitation of digital trade through the ongoing joint statement initiative on e-commerce (JSI); Indonesia Ministry of Trade Import Licensing Regulations; Committee on Foreign Investment in the United States (CFIUS) concerns, specifically regarding the U.S. Governments foreign investment review of Nippon Steels proposed acquisition of U. S. Steel; supply chain and defense industrial base issues; printed circuit boards
Client expense: $14,750,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Executive Office of the President (EOP), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
2024 · third_quarter · Health Issues
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act H.R. 3800, Chronic Disease Flexible Coverage Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6860, Restore Protections for Dialysis Patients Act H.R. 9029, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 S. 2780, The Medication Affordability and Patent Integrity Act Proposed Rule, Internal Revenue Service, the Employee Benefits Security Administration, and the Health and Human Services Department; Requirements Related to the Mental Health Parity and Addiction Equity Act (88 Fed. Reg. 51,552-51,669, August 3, 2023) Proposed Rule, Employee Benefits Security Administration, Department of Labor; Definition of Employer-Association Health Plans (88 Fed. Reg. 87,968-87,981, December 20, 2023) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191-1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act(PAHPA, P.L. 109-417); over-the-counter preventive services; ERISA preemption protections including information on constructive changes/modifications to ERISA; efforts to reform the World Health Organizations (WHO) engagement with private sector; support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment, addressing trade barriers, strengthening the global supply chain, and raising awareness on potential pitfalls of local manufacturing; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Client expense: $14,750,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR)
2024 · third_quarter · Trade (domestic/foreign)
H.R. 4307: Medical Supply Chain Resiliency Act H.R. 7085: BIOSECURE Act S. 1956: Invent Here, Make Here Act of 2024 S. 2115: Medical Supply Chain Resiliency Act S. 3558: Prohibiting Foreign Access to American Genetic Information Act of 2024 Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues
Client expense: $6,880,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Trade (domestic/foreign)
Issues related to promoting a trade agenda on health-related issues, including H.R.4307/S.2115 - Medical Supply Chain Resiliency Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Health Issues
340B legislation. Issues related to vaccine injury compensation funds. S.2115/H.R.4307 - Medical Supply Chain Resiliency Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Trade (domestic/foreign)
International Supply Chain HR4307/S2115 - Medical Supply Chain Resiliency Act
Client expense: $970,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
2024 · third_quarter · Health Issues
H.R. 5013, the Value in Health Care Act, all provisions. H.R. 2584, the SAVE Act of 2023, all provisions. H.R. 4307 and S. 2115, the Medical Supply Chain Resiliency Act, all provisions. Requested signatures on a letter opposing a company's unilateral decision to change their form of participation in the 340B Drug Discount Program.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · third_quarter · Health Issues
H.R. 766/S. 114, Preventive Health Savings Act H.R. 2888/S. 44, ONSHORE Manufacturing Act H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6033, Supporting Patient Education and Knowledge Act S. 2333, Pandemic and All-Hazards Preparedness and Response Act S. 5218, A bill to amend titles XI and XVIII of the Social Security Act to strengthen, increase oversight of, and compliance with, security standards for health information, and for other purposes (RIN 0955-AA06)Office of the National Coordinator for Health Information Technology -Health Data, Technology, and Interoperability: Patient Engagement, Information Sharing, and Public Health Interoperability (HTI-2) Proposed Rule FDA-2017-D-0154 Food and Drug Administration- Considerations in Demonstrating Interchangeability with a Reference Product: Update CISA-2022-0010, Department of Homeland Security, Cybersecurity and Infrastructure Security Agency - Cyber Incident Reporting for Critical Infrastructure Act (CIRCIA) Reporting Requirements
Client expense: $110,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE
2024 · first_quarter · Health Issues
General health issues; H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act; H.R. 7174, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Trade (domestic/foreign)
H.R. 405: Essential Medicines Strategic Stockpile Act of 2023 H.R. 4307: Medical Supply Chain Resiliency Act H.R. 3858: No Free TRIPS Act H.R. 7085: BIOSECURE Act S. 845: Short on Competition Act S. 1834: No Free TRIPS Act S. 2115: Medical Supply Chain Resiliency Act S. 3558: BIOSECURE Act Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues
Client expense: $1,510,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2024 · second_quarter · Health Issues
340B legislation. Issues related to vaccine injury compensation funds. S.2115/H.R.4307 - Medical Supply Chain Resiliency Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Health Issues
Implementation of the drug pricing provisions in the Inflation Reduction Act Access to Prescription Digital Therapeutics Act (H.R. 1458)S. 2115/H.R. 4307 the Medical Supply Chain Resiliency ActH.R. 8816, the American Medical Innovation and Investment Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Trade (domestic/foreign)
H.R. 405: Essential Medicines Strategic Stockpile Act of 2023 H.R. 4307: Medical Supply Chain Resiliency Act H.R. 7085: BIOSECURE Act S. 1956: Invent Here, Make Here Act of 2023 S. 1834: No Free TRIPS Act S. 2115: Medical Supply Chain Resiliency Act S. 3558: BIOSECURE Act Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues
Client expense: $6,960,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Trade (domestic/foreign)
H.R. 813, Global Investment in American Jobs Act H.R. 3739/S. 2343, For Accurate Import Relief To Aid Retailers and Importers of Foreign Freights (FAIR TARIFF) Act of 2023 H.R. 3882/S. 1856, Leveling the Playing Field Act 2.0 H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 5614/S. 552, Haiti Economic Lift Program Extension Act of 2023 H.R. 6349, Preventing Adversaries from Developing Critical Capabilities Act H.R. 6555, CNL Update Act of 2023 H.R. 6614, Maintaining American Superiority by Improving Export Control Transparency Act H.R. 6990, Digital Trade for Development Act H.R. 7151, Export Control Enforcement and Enhancement Act H.R. 7571/S. 3878, The Americas Act H.R. 7962, United States Trade Leadership in the Indo-Pacific Act H.R. 8249, U.S.-Africa Strategic Trade and Investment Partnership Act of 2024 H.R. 8299, Maximizing Israel-U.S. Research Advancement and Collaborative Leadership in Emerging Medical Technology Act of 2024 H.R. 8315, Enhancing National Frameworks for Overseas Restriction of Critical Exports Act S. 913, Innovation and Development in Ecuador (IDEA) Act of 2023 S. 1325, Western Hemisphere Partnership Act of 2023 S. 1421, Country of Origin Labeling (COOL) Online Act S. 1926, United States-Uruguay Economic Partnership Act S. 2321, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2024 S. 3431, Customs Modernization Act of 2023 S. 4110, AGOA Renewal and Improvement Act of 2024 S. 1969, De Minimis Reciprocity Act of 2023 H.Res. 1056, Recognizing the importance of trilateral cooperation among the United States, Japan, and South Korea Draft legislation titled Fiscal Year 2025 Commerce, Justice, Science, and Related Agencies Appropriations Act Draft legislation titled Protecting American Innovation and Development Act of 2024 Draft legislation to limit the availability of civil actions affected by Russia sanctions Notice of Proposed Rulemaking, Federal Trade Commission; Unfair or Deceptive Fees Rule; Commission Matter No. R207011 (88 Fed. Reg. 77,420-77,485, November 9, 2023) Request for Comments, Office of the United States Trade Representative; Initiation of Section 301 Investigation: China's Acts, Policies, and Practices Targeting the Maritime, Logistics, and Shipbuilding Sectors for Dominance (89 Fed. Reg. 29,424-29,426, April 22, 2024) Request for Comment, Office of the United States Trade Representative; Promoting Supply Chain Resilience (89 Fed. Reg. 16,608-16,610, March 7, 2024) Notice of Informal Hearing, Federal Trade Commission; Trade Regulation Rule on Unfair or Deceptive Fees (89 Fed. Reg. 21,216-21,222, March 27, 2024) Various issues relating to U.S.-Korea digital trade and services; Generalized System of Preferences (GSP) reauthorization; ratification of the Assignment of Receivables in International Trade Convention; reform of the World Trade Organization (WTO); reforms to export controls; digital trade; investor protections in trade agreements; implementation of the United States-Mexico-Canada trade agreement (USMCA); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of the Uyghur Forced Labor Prevention Act (UFLPA) (P.L. 117-78); implementation of the Creating Helpful Incentives to Produce Semiconductors (CHIPS) and Science Act, (P.L. 117-167); reform of Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); reform of Section 301 of the Trade Act of 1974 (P.L. 93-618), including establishment of exclusion process; implementation of the African Growth and Opportunity Act (P.L. 106-200); International Emergency Economic Powers Act (IEEPA), Title II of (P. L. 95-223); implementation of the INFORM Consumers Act, Div. BB, Title III of (P. L. 117-328); implementation of the Inflation Reduction Act, (P.L. 117-169); implementation of the Build America, Buy America Act (BABA) statute contained in the Infrastructure Investment and Jobs Act (P.L. 117-58); Foreign Assistance Act for Fiscal Year 2024; development of the National Defense Authorization Act for Fiscal Year 2025; implementation of the National Defense Authorization Act for Fiscal Year 2024; reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); pharmaceutical price controls; domain name system abuse and related IP issues; implementation of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; efforts related to the reauthorization of the African Growth and Opportunity Act (AGOA) (P.L. 106-200); China's intellectual property regime, industrial policies, and cyber security; implementation of the U.S.- China economic and trade agreement; IP issues relating to trade secret theft; IP issues relating to internet counterfeiting and piracy; IP issues relating to artificial intelligence; implementation of U.S. sanctions on Russia including those related to Russias threats to and invasion of Ukraine; efforts related to sustaining momentum on providing aid to Ukraine; U.S. sanctions on Turkey; U.S.-EU negotiations on a legal data transfer mechanism; U.S.-EU energy and sustainability cooperation; United States-India Trade Policy Forum; EU and international tax policy including digital tax proposals; U.S.-EU Trade & Technology Council; EU-U.S. Joint Technology Competition Policy Dialogue; EU Digital Markets Act; EU Digital Services Act; EU Data Act; EU AI Act; EU Carbon Border Adjustment Mechanism; EU digital sovereignty and regulatory agenda; European Cybersecurity Certification Scheme for Cloud Services (EUCS); Global Internet Governance; Global Cross Border Privacy Rules Forum; concerns related to Protecting Americans Data from Foreign Adversaries Act; digital-related policies in the G20, G7, OECD, and other international fora; Indias Information Communications Technology (ICT) Tariffs; Federal Trade Commission statutory authority under Section 19 of the Federal Trade Commission Act of 1914; efforts to modernize the Committee on Foreign Investment in the United States (CFIUS); efforts related to the National Defense Authorization Act for Fiscal Year 2025; efforts to preserve investment protections such as investor-state dispute settlement; efforts related to outlining critical mineral opportunities with key allies; efforts related to the 2024 Farm Bill; efforts related to opposing international imposition of digital services taxes; related efforts supporting strong digital trade rules; efforts related to the negotiation of the U.S. - EU Arrangements on Global Steel and Aluminum Excess Capacity and Carbon Intensity; efforts to modify permanent normal trade relations treatment with China; U.S. economic and commercial relations with key trading partners across the globe; efforts to draft and implement an outbound investment screening mechanism; efforts related to establishing a domestic carbon border tax mechanism, foreign pollution fees; efforts related to modernizing customs processes and updating tariff application procedures including revisions to the de minimus statute; efforts to revise country of origin labeling requirements for animal and online products; efforts related to boosting trade relations with the Latin American region; efforts related to electric vehicle tax credit incentives in the Inflation Reduction Act (P.L. 117-169); efforts related to the development and implementation of the Indo-Pacific Economic Framework (IPEF); efforts related to the development and negotiation of the U.S.-Taiwan Initiative on 21st Century Trade: efforts related to the development and negotiation of the Americas Partnership for Economic Prosperity (APEP); efforts related to the development and negotiation of the U.S.-UK Dialogue on the Future of Atlantic Trade; efforts related to the development and negotiation of the U.S.-Kenya Strategic Trade and Investment Partnership; efforts to significantly revise U.S. antidumping and countervailing duty law; efforts to provide financial support, trade facilitation, and infrastructure support to the African Continental Free Trade Area (AfCFTA); implementation and enforcement of U.S. free-trade agreements in force with Canada and Mexico (the United States-Mexico-Canada Agreement), the Dominican Republic-Central America Free Trade Agreement (CAFTA-DR FTA), Colombia and South Korea; implementation and enforcement of the agreements and ongoing negotiations of the World Trade Organization (WTO); efforts related to the Export-Import Bank (Ex-Im Bank); trade policy consideration addressing cross-border data flows and issues of forced localization, and forced disclosure of source code; tax treaties with Poland and Croatia; international trade and regulatory practices impacting digital goods and services; international competition policy and related regulations; international artificial intelligence policy; international 5G policy and telecommunications infrastructure; international cybersecurity policy; international policies on standards development; international policies on data privacy; international digital health policies; international policies related to content moderation and intermediary liability; digital trade policy consideration, including cross-border data flows, data localization, and forced disclosure of source code; advancing international regulatory cooperation; efforts related to the U.S.-Bangladesh Trade and Investment Cooperation Forum Agreement (TICFA); efforts related to the resumption of the U.S.-Bangladesh High Level Economic Consultation; efforts related to the U.S.-India Innovation Handshake and the India-U.S. Defense Acceleration Ecosystem (INDUS-X); steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and the United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; trade negotiations and trade priorities between the U.S. and China; U.S.-Brazil trade; Pacific Digital Trade Agreements; East Coast port trade negotiations; U.S. Chile Tax Treaty, Convention for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital; U.S. Trade Representative section 301 investigation of Frances digital services tax; efforts to pass the Miscellaneous Tariff bill; Trade Promotion Authority (TPA) reauthorization and reform; Russian sovereign debt; Commercial Service Office in Bangladesh; Indo-Pacific Economic Framework and associated issues, digital trade de minimus level for duty free clearance of low value goods, competition provisions; patent examination practices and patent quality measures; tech transfer frameworks under the Bayh-Dole Act (P.L. 96-517); recommendations for Export Controls Cooperation at the U.S.-EU Trade and Technology Council; adoption of digital clothing labels; international competition policy, specifically FTC and DOJ involvement in the European Unions implementation of the EU Digital Markets Act; compliance with sanctions on the Russian Federation and potential legal penalties in Russian courts for U.S. companies; proposal for General License Authorizing Private Commercial Arbitration Proceedings Involving Blocked Persons; The United States Trade Representatives decision to withdraw support for digital trade in the context of World Trade Organizations e-commerce negotiations; support for robust global framework for facilitation of digital trade through the ongoing joint statement initiative on e-commerce (JSI); Indonesia Ministry of Trade Import Licensing Regulations; supply chain and defense industrial base issues; printed circuit boards
Client expense: $13,930,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Executive Office of the President (EOP), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
2024 · second_quarter · Health Issues
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6860, Restore Protections for Dialysis Patients Act S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Draft legislation titled Fiscal Year 2025 Labor, Health and Human Services, Education, and Related Agencies Appropriations Act Request for Extension of Time for Comments, on Proposed Rule, Consumer Financial Protection Bureau; Prohibition on Creditors and Consumer Reporting Agencies Concerning Medical Information (Regulation V) (89 Fed. Reg. 51,682-51,736, June 18, 2024) Proposed Rule, Internal Revenue Service, the Employee Benefits Security Administration, and the Health and Human Services Department; Requirements Related to the Mental Health Parity and Addiction Equity Act (88 Fed. Reg. 51,552-51,669, August 3, 2023) Proposed Rule, Employee Benefits Security Administration, Department of Labor; Definition of Employer-Association Health Plans (88 Fed. Reg. 87,968-87,981, December 20, 2023) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; legislative proposals to tax employer-provided health care coverage; artificial price caps on providing insulin; Reasonable Price Clause in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); over-the-counter preventive services; ERISA preemption protections including information on constructive changes/modifications to ERISA; artificial price caps on providing insulin; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment and addressing trade barriers; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Client expense: $13,930,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR)
H.R. 4307: Medical Supply Chain Resiliency Act S. 1834/H.R. 3858: No Free TRIPS Act S. 845: Short on Competition Act S. 2115: Medical Supply Chain Resiliency Act Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues
Client expense: $1,010,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office
2024 · second_quarter · Trade (domestic/foreign)
International Supply Chain HR4307/S2115 - Medical Supply Chain Resiliency Act
Client expense: $2,450,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2024 · second_quarter · Trade (domestic/foreign)
Tariff policy U.S.-EU trade U.S.-UK trade IPEF USMCA Enforcement Universal Postal Union Access and Reform H.R. 4307/ S.2115 - Medical Supply Chain Resiliency Act: Promotes a trusted trader network for the movement of essential medical goods across borders. The legislation will improve U.S. access, and ensure that critical goods can be delivered safely, swiftly, and efficiently to patients at home and around the world. S 986 - STOP Act 2.0 - makes it illegal for foreign shippers to mis-represent the origin of international postal shipments and increases customs and security compliance visibility
Client expense: $1,050,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, Small Business Administration (SBA), State, Dept of (DOS), U.S. Trade Representative (USTR)
2024 · second_quarter · Health Issues
H.R. 5013, the Value in Health Care Act, all provisions. H.R. 2584, the SAVE Act of 2023, all provisions. H.R. 4307 and S. 2115, the Medical Supply Chain Resiliency Act, all provisions. S. XXXX, the Labor, Health and Human Services and Education Appropriations Act of FY 2025, requested funding for a project.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Health Issues
Incentivizing domestic manufacturing of critical medical supplies Issues related to health care costs and transparency Electronic prior authorization and administrative simplification Health care supply chain resiliency 340B Drug discount program Reauthorization of Pandemic and All Hazards Preparedness Act Hospital finance issues Healthcare workforce issues (graduate medical education, health professional training, recruitment and retention, minimum staffing requirements) Medicare payment policies Alternative payment models and related policies Medicare home infusion policy Reauthorization of Substance-Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act Expanding access to interoperable health tech in long term and post-acute care settings Maternal and infant health Health care workplace violence and worker safety S. 148 Stop STALLING Act Medicaid Disproportionate Hospital Share cuts S. 2115, H.R. 4307 Medical Supply Chain Resiliency Act H.R. 4104, S. 1976 Preseving Patients Access to Home Infusion Act H.R. 2584, S. 2768 SAVE Act H.R. 3577 Medical and Health Stockpile Accountability Act H.R. 2665 Supporting Safety Net Hospitals Act H.R. 2389, S. 1302 Resident Physician Shortage Reduction Act H.R. 3346 IMPACT to Save Moms Act H.R. 5378 Lower Costs, More Transparency Act S. 2840 Bipartisan Primary Care and Health Workforce Act H.R. 5013, S. 3503 Value in Health Care Act H.R. 4942, S. 665 Conrad State 30 and Physician Access Reauthorization Act Artificial intelligence in healthcare H.R.766, S. 114 Preventive Health Savings Act H.R. 6205, S. 3211 Healthcare Workforce Resilience Act H.R. 7050 Substance Use Disorder Workforce Act H.R. 8702, S. 4532 Improving Seniors' Timely Access to Care Act H.R. 7855 Rural Residency Planning and Development Act
Client expense: $225,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · second_quarter · Trade (domestic/foreign)
Issues related to promoting a trade agenda on health-related issues, including S. 2115/H.R. 4307 - Medical Supply Chain Resiliency Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2024 · first_quarter · Trade (domestic/foreign)
H.R. 405: Essential Medicines Strategic Stockpile Act of 2023 H.R. 4307: Medical Supply Chain Resiliency Act H.R. 3858: No Free TRIPS Act H.R. 7085: BIOSECURE Act S. 845: Short on Competition Act S. 1834: No Free TRIPS Act S. 2115: Medical Supply Chain Resiliency Act S. 3558: BIOSECURE Act Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues
Client expense: $820,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2024 · first_quarter · Trade (domestic/foreign)
H.R. 405: Essential Medicines Strategic Stockpile Act of 2023 H.R. 4307: Medical Supply Chain Resiliency Act H.R. 3858: No Free TRIPS Act H.R. 7085: BIOSECURE Act S. 845: Short on Competition Act S. 1834: No Free TRIPS Act S. 2115: Medical Supply Chain Resiliency Act S. 3558: BIOSECURE Act Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues
Client expense: $9,600,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
2024 · first_quarter · Trade (domestic/foreign)
H.R. 760, Chinese Military and Surveillance Company Sanctions Act of 2023 H.R. 813, Global Investment in American Jobs Act H.R. 3136, National Critical Capabilities Defense Act of 2023 H.R. 3739/S. 2343, For Accurate Import Relief To Aid Retailers and Importers of Foreign Freights (FAIR TARIFF) Act of 2023 H.R. 3882/S. 1856, Leveling the Playing Field Act 2.0 H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 5375, Strengthening the Quad Act H.R. 5613, Sanctions Lists Harmonization Act H.R. 5614/S. 552, Haiti Economic Lift Program Extension Act of 2023 H.R. 6349, Preventing Adversaries from Developing Critical Capabilities Act H.R. 6555, CNL Update Act of 2023 H.R. 6614, Maintaining American Superiority by Improving Export Control Transparency Act H.R. 6990, Digital Trade for Development Act H.R. 7085, BIOSECURE Act H.R. 7151, Export Control Enforcement and Enhancement Act H.R. 7476, The Countering Communist China Act H.R. 7520, Protecting Americans Data from Foreign Adversaries Act of 2024 H.R. 7571/S. 3878, The Americas Act S. 686, Restricting the Emergence of Security Threats that Risk Information and Communications Technology (RESTRICT) Act S. 913, Innovation and Development in Ecuador (IDEA) Act of 2023 S.1325, Western Hemisphere Partnership Act of 2023 S.1421, Country of Origin Labeling (COOL) Online Act S.1926, United States-Uruguay Economic Partnership Act S. 2321, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2024 S. 3558, Prohibiting Foreign Access to American Genetic Information Act of 2024 Draft legislation to limit the availability of civil actions affected by Russia sanctions Draft legislation titled GUARD Act Draft legislation titled the United States Trade Leadership in the Indo-Pacific Act Draft legislation titled the U.S.-Africa Strategic Trade and Investment Partnership Act of (ASTIP) Draft legislation on comprehensive U.S.-Israel health and innovation collaboration Various issues relating to U.S.-Korea digital trade and services; Generalized System of Preferences (GSP) reauthorization; ratification of the Assignment of Receivables in International Trade Convention; reform of the World Trade Organization (WTO); reforms to export controls; implementation of the United States-Mexico-Canada trade agreement (USMCA); implementation of the American Manufacturing Competitiveness Act of 2016 (P.L.114-159); implementation of the Trade Facilitation and Trade Enforcement Act of 2015 (P.L. 114-125); implementation of the Uyghur Forced Labor Prevention Act (UFLPA) (P.L. 117-78); implementation of the Creating Helpful Incentives to Produce Semiconductors (CHIPS) and Science Act, (P.L. 117-167); reform of Section 232 of the Trade Expansion Act of 1962 (P.L. 87-794); reform of Section 301 of the Trade Act of 1974 (P.L. 93-618), including establishment of exclusion process; implementation of the African Growth and Opportunity Act (P.L. 106-200); International Emergency Economic Powers Act (IEEPA), Title II of (P. L. 95-223); implementation of the INFORM Consumers Act, Div. BB, Title III of (P. L. 117-328); implementation of the Inflation Reduction Act, (P.L. 117-169); implementation of the Build America, Buy America Act (BABA) statute contained in the Infrastructure Investment and Jobs Act (P.L. 117-58); Foreign Assistance Act for Fiscal Year 2024; Development of the National Defense Authorization Act for Fiscal Year 2025; reauthorization of the Customs-Trade Partnership Against Terrorism (CTPAT); pharmaceutical price controls; domain name system abuse and related IP issues; WTO Trade-Related Intellectual Property Rights (TRIPS) waiver and related forced technology transfer measures; World Health Organization (WHO) pandemic agreement; implementation of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement; Office of the Intellectual Property Enforcement Coordinator and the National Intellectual Property Rights Coordination Center; patent linkage and regulatory data protection; efforts related to the reauthorization of the African Growth and Opportunity Act (AGOA) (P.L. 106-200); China's intellectual property regime industrial policies and cyber security; implementation of the U.S.- China economic and trade agreement; IP issues relating to trade secret theft; IP issues relating to internet counterfeiting and piracy; IP issues relating to artificial intelligence; implementation of U.S. sanctions on Russia including those related to Russias threats to and invasion of Ukraine; U.S. sanctions on Turkey; U.S.-EU negotiations on a legal data transfer mechanism; U.S.-EU energy and sustainability cooperation; United States-India Trade Policy Forum; EU and international tax policy including digital tax proposals; U.S.-EU Trade & Technology Council; EU-U.S. Joint Technology Competition Policy Dialogue; EU Digital Markets Act; EU Digital Services Act; EU Data Act; EU AI Act; EU Carbon Border Adjustment Mechanism; EU digital sovereignty and regulatory agenda; European Cybersecurity Certification Scheme for Cloud Services (EUCS); Global Internet Governance; Global Cross Border Privacy Rules Forum; Digital-related policies in the G20, G7, OECD, and other international fora; Indias Information Communications Technology (ICT) Tariffs; Federal Trade Commission statutory authority under Section 19 of the Federal Trade Commission Act of 1914; efforts to modernize the Committee on Foreign Investment in the United States (CFIUS); efforts related to the 2024 Farm Bill; efforts related to opposing international imposition of digital services taxes; related efforts supporting strong digital trade rules; efforts related to the negotiation of the U.S. - EU Arrangements on Global Steel and Aluminum Excess Capacity and Carbon Intensity; efforts to modify permanent normal trade relations treatment with China & Kazakhstan; U.S. economic and commercial relations with key trading partners across the globe; efforts to draft and implement an outbound investment screening mechanism; efforts related to establishing a domestic carbon border tax mechanism, foreign pollution fees; efforts related to modernizing customs processes and updating tariff application procedures including revisions to the de minimus statute; efforts to revise country of origin labeling requirements for animal and online products; efforts related to boosting trade relations with the Latin American region; efforts related to electric vehicle tax credit incentives in the Inflation Reduction Act (P.L. 117-169); efforts related to the development and negotiation of the Indo-Pacific Economic Framework (IPEF); efforts related to the development and negotiation of the U.S.-Taiwan Initiative on 21st Century Trade; efforts related to the development and negotiation of the Americas Partnership for Economic Prosperity (APEP); efforts related to the development and negotiation of the U.S.-UK Dialogue on the Future of Atlantic Trade; efforts related to the development and negotiation of the U.S.-Kenya Strategic Trade and Investment Partnership; efforts to significantly revise U.S. antidumping and countervailing duty law; efforts to provide financial support, trade facilitation, and infrastructure support to the African Continental Free Trade Area (AfCFTA); implementation and enforcement of U.S. free-trade agreements in force with Canada and Mexico (the United States-Mexico-Canada Agreement), the Dominican Republic-Central America Free Trade Agreement (CAFTA-DR FTA), Colombia and South Korea; Implementation and enforcement of the agreements and ongoing negotiations of the World Trade Organization (WTO); efforts related to the Export-Import Bank (Ex-Im Bank); trade policy consideration with regard to cross-border data flows and issues of forced localization, and forced disclosure of source code; tax treaties with Poland and Croatia; international trade and regulatory practices impacting digital goods and services; international competition policy and related regulations; international artificial intelligence policy; international 5G policy and telecommunications infrastructure; international cybersecurity policy; international policy on standards development; international policies related to content moderation and intermediary liability; advancing international regulatory cooperation; steel and aluminum tariffs; trade policy concerns regarding customs duties on electronic transmissions; trade negotiations and trade priorities between the U.S. and the European Union; trade negotiations and trade priorities between the U.S. and the United Kingdom; trade negotiations and trade priorities between the U.S. and Japan; trade negotiations and trade priorities between the U.S. and China; U.S.-Brazil trade; Pacific Digital Trade Agreements; U.S. Chile Tax Treaty, Convention for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital; U.S. Trade Representative section 301 investigation of Frances digital services tax; efforts to pass the Miscellaneous Tariff bill; Trade Promotion Authority (TPA) reauthorization and reform; Russian sovereign debt; Commercial Service Office in Bangladesh; Indo-Pacific Economic Framework and associated issues, digital trade de minimus level for duty free clearance of low value goods, competition provisions; patent examination practices and patent quality measures; tech transfer frameworks under the Bayh-Dole Act (P.L. 96-517); recommendations for Export Controls Cooperation at the U.S.-EU Trade and Technology Council; adoption of digital clothing labels; international competition policy, specifically FTC and DOJ involvement in the European Unions implementation of the EU Digital Markets Act; compliance with sanctions on the Russian Federation and potential legal penalties in Russian courts for U.S. companies; proposal for General License Authorizing Private Commercial Arbitration Proceedings Involving Blocked Persons; The United States Trade Representatives decision to withdraw support for digital trade in the context of World Trade Organizations e-commerce negotiations; supply chain and defense industrial base issues; printed circuit boards; customs modernization legislation; legislation to alter de minimus policies
Client expense: $23,370,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Defense, Dept of (DOD), Energy, Dept of, Executive Office of the President (EOP), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Intl Trade Administration (ITA), Justice, Dept of (DOJ), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Copyright Office, U.S. Customs & Border Protection, U.S. Trade Representative (USTR)
2024 · first_quarter · Health Issues
H.R. 1264, Commonsense Reporting Act of 2023 H.R. 2813, Self-Insurance Protection Act H.R. 2868, Association Health Plans Act H.R. 4307/S. 2115, Medical Supply Chain Resiliency Act H.R. 6860, Restore Protections for Dialysis Patients Act S. 127, Pharmacy Benefit Manager Transparency Act of 2023 S. 142, Preserve Access to Affordable Generics and Biosimilars Act S. 148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act S. 150, Affordable Prescriptions for Patients Act of 2023 S. 1067, Ensuring Timely Access to Generics Act of 2023 S. 1114, Expanding Access to Low-Cost Generics Act of 2023 S. 1214, Retaining Access and Restoring Exclusivity (RARE) Act S. 1339, Pharmacy Benefit Manager Reform Act S. 2624, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024 Proposed Rule by the Internal Revenue Service, the Employee Benefits Security Administration, and the Health and Human Services Department; Requirements Related to the Mental Health Parity and Addiction Equity Act (88 Fed. Reg. 51,552-51,669, August 3, 2023) Proposed Rule, Employee Benefits Security Administration, Department of Labor; Definition of Employer-Association Health Plans (88 Fed. Reg. 87,968-87,981, December 20, 2023) Various issues relating to the employer-sponsored health care system, implementation of regulatory process, provider network adequacy, health savings account (HSAs), health reimbursement account (HRAs), employer mandate; Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2026, and Solicitation of Comments; implementation of the American Rescue Plan Act (P.L. 117-2); implementation of the Inflation Reduction Act (P.L. 117-169); "Reasonable Price Clause" in reauthorization draft of the Pandemic and All Hazards Preparedness Act (PAHPA, P.L. 109-417); balance or surprise billing and related issues; single-payer health care options; health reimbursement arrangements and other account-based group health plans; Health and Human Services international pricing index (IPI) model; mental health parity; drug pricing; COBRA subsidies; Federal Trade Commissions multilateral pharmaceutical merger taskforce; telehealth, including coverage of telehealth under High Deductible Health Plans (HDHPs) and expanding telehealth options for employees; impact of Pharmacy Benefit Managers Practices; FTC-2022-0015; petition to HHS to grant march-in rights for the patents on the drug Xtandi; Over-the-counter preventive services; ERISA preemption protections including information on constructive changes/modifications to ERISA; artificial price caps on providing insulin; efforts to reform the World Health Organizations (WHO) engagement with private sector; continued U.S. membership to the World Health Organization (WHO); support for necessary market conditions to incentivize health sector investment from private sector; support for private sector involvement in health systems strengthening; promote greater harmonization of standards and investment in digital health; health-related policy issues in the G20/G7 forums and other multilateral forums; support for improving access to health products and technologies globally, including via regulatory alignment and addressing trade barriers; Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies, U.S. Centers for Medicare & Medicaid Services, U.S. Department of Health and Human Services (2025 Advance Notice, January 31, 2024)
Client expense: $23,370,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Labor, Dept of (DOL), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade & Development Agency (USTDA), U.S. Trade Representative (USTR)
Expensing of R&D Expenditures Foreign Drug Data Protection Laws H.R. 4307: Medical Supply Chain Resiliency Act S. 1834/H.R. 3858: No Free TRIPS Act S. 845: Short on Competition Act S. 2115: Medical Supply Chain Resiliency Act Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues
Client expense: $3,510,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR), White House Office